Compare Apple Inc (AAPL) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs BioNano Genomics Inc — how do they compare? Apple Inc trades at $304.07 (market cap $4.45T), while BioNano Genomics Inc trades at $1.17 (market cap $13.66M). The key difference: Apple Inc is far larger — about 325768.7× BioNano Genomics Inc's market cap, and Apple Inc pays a 0.35% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| AAPL | BNGO | |
|---|---|---|
Market Cap | $4.45T | $13.66M |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $4.92 |
52-Week Low | $224.90 | $1.06 |
Enterprise Value | $4.47T | $16.26M |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and near-term support at $306. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Analyst consensus is bullish with a $337.63 price target, though recent news highlights union disputes and potential Q3 earnings pressure.
Outlook remains positive driven by AI opportunities and a massive device ecosystem, but risks include weaker iPhone sales, regulatory scrutiny, and union tensions. The stock offers growth potential with solid cash flow, yet investors should weigh near-term headwinds against long-term strengths.
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
